Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer exchanges : Amex save search
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 5.24%
H: 2.71%
C: -4.75%
cancer pancreatic deal
Antech launches breakthrough in-hospital innovation, Nu.Q® Canine Cancer Test
Published: 2024-01-12 (Crawled : 13:00) - prnewswire.com
VNRX | $0.8 -5.88% 0.0% 350K
|
Health Technology
|
| O: 1.74%
H: 15.59%
C: 14.66%
test cancer
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 0.0%
H: 1.23%
C: -4.92%
cancer pancreatic treatment namodenoson
American Shared Hospital Services Enters Into Agreement to Acquire 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island
Published: 2023-11-20 (Crawled : 12:30) - globenewswire.com
AMS | $3.02 0.84% 1.62% 1
|
Health Services
|
| O: -1.23%
H: 2.9%
C: 1.45%
services hospital cancer acquire agreement therapy
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
VNRX | $0.8 -5.88% 0.0% 350K
|
Health Technology
|
| O: 2.93%
H: 10.12%
C: 3.95%
test cancer blood
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
CVM | $1.46 -0.68% 0.0% 6
|
Health Technology
|
| O: 0.86%
H: 4.26%
C: -6.84%
multikine approval cancer treatment
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 5.79%
H: 1.82%
C: -8.76%
association cancer pancreatic treatment namodenoson research
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
Published: 2023-07-24 (Crawled : 13:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 750K
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -1.41%
lung report cancer cell treatment research topline therapeutics results study
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 1.97%
H: 2.43%
C: 0.32%
award liver granted asco cancer treatment namodenoson
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
Published: 2023-07-14 (Crawled : 15:00) - biospace.com/
CVM | $1.46 -0.68% 0.0% 6
|
Health Technology
|
| O: -0.85%
H: 12.07%
C: 10.34%
fda approval positive cancer meeting
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
Published: 2023-07-11 (Crawled : 15:00) - biospace.com/
CVM | $1.46 -0.68% 0.0% 6
|
Health Technology
|
| O: 2.89%
H: 1.2%
C: -3.21%
biomarker cancer tumor potential
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
Published: 2023-05-15 (Crawled : 12:00) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: -1.4%
europe cancer pancreatic potential
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Published: 2023-05-02 (Crawled : 12:00) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: 13.14%
H: 2.02%
C: 1.01%
cancer pancreatic molecular
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
Published: 2023-04-19 (Crawled : 22:00) - biospace.com/
CVM | $1.46 -0.68% 0.0% 6
|
Health Technology
|
| O: 1.63%
H: 17.6%
C: 13.2%
multikine approval cancer treatment
Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
Published: 2023-04-19 (Crawled : 14:00) - biospace.com/
ATNM | $7.06 1.44% 2.83% 28
|
Health Technology
|
| O: -0.86%
H: 1.73%
C: -0.54%
cancer meeting
Cervical Cancer Screening Global Market Report 2023: Sector to Reach $34.92 Billion by 2028 at a 4.6% CAGR
Published: 2023-04-18 (Crawled : 15:20) - prnewswire.com
PKX | News | $71.38 -0.14% 0.98% 150K
|
Non-Energy Minerals
|
| O: -0.74%
H: 0.51%
C: 0.32%
ABT | News | $106.89 -0.65% -0.09% 4.2M
|
Health Technology
|
| O: 0.88%
H: 0.25%
C: -1.22%
NHC | $91.13 -0.06% 0.0% 38K
|
Health Services
|
| O: -0.33%
H: 0.0%
C: -0.85%
report cancer global market
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
Published: 2023-04-07 (Crawled : 13:00) - globenewswire.com
OCX | News | $2.46 0.2% -6.74% 40K
|
Health Technology
| Email alert
Add to watchlist
cancer publication results study
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
Published: 2023-03-08 (Crawled : 18:00) - biospace.com/
CVM | $1.46 -0.68% 0.0% 6
|
Health Technology
|
| O: 0.69%
H: 3.78%
C: -5.84%
extension multikine cancer study
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A
Published: 2023-02-06 (Crawled : 13:00) - biospace.com/
ATNM | $7.06 1.44% 2.83% 28
|
Health Technology
|
| O: 0.74%
H: 1.3%
C: -1.79%
research agreement cancer
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.